Drug intelligence / Profile preview

Empower

Development stage: Unknown
Lead developer: Elevai Labs
Modality: Recombinant Proteins and Enzymes, Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

Empower is a topical exosome-based skin serum developed by Elevai Skincare and acquired by Carmell Corporation. It is formulated using human umbilical mesenchymal stem cell (hUMSC) derived exosomes, which are rich in growth factors, cytokines, and peptides. The product is primarily indicated for post-procedure skin recovery (e.g., after laser or microneedling) and general skin rejuvenation. By delivering these signaling molecules directly to the skin, Empower aims to reduce inflammation, accelerate the healing process, and stimulate collagen production to improve skin texture and appearance.

Brand names: Elevai EmpowerEmpower
Other names: Elevai Empower Topical Exosome Serum

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on Empower.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Empower.

Explore the full profile